Shanghai Runda Medical Technology Co., Ltd. (603108.SS)
CNY 18.12
(3.13%)
CNY 18.12
(3.13%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 646.8 Million CNY | -50.49% |
| 2022 | 1.43 Billion CNY | 25.0% |
| 2021 | 1.15 Billion CNY | 14.84% |
| 2020 | 1 Billion CNY | -4.79% |
| 2019 | 1.05 Billion CNY | 82.23% |
| 2018 | 577.73 Million CNY | 51.78% |
| 2017 | 380.63 Million CNY | 119.33% |
| 2016 | 173.54 Million CNY | 45.07% |
| 2015 | 119.62 Million CNY | 24.75% |
| 2014 | 95.89 Million CNY | 9.03% |
| 2013 | 87.95 Million CNY | 20.36% |
| 2012 | 73.07 Million CNY | 2.67% |
| 2011 | 71.17 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 132.53 Million CNY | -5.1% |
| 2024 Q2 | 148.62 Million CNY | 12.14% |
| 2024 Q3 | 67.26 Million CNY | -54.74% |
| 2023 Q3 | 204.93 Million CNY | 8.88% |
| 2023 Q4 | 139.65 Million CNY | -31.85% |
| 2023 FY | 712.37 Million CNY | -50.49% |
| 2023 Q1 | 152.15 Million CNY | -21.66% |
| 2023 Q2 | 188.22 Million CNY | 23.7% |
| 2022 Q2 | 344.33 Million CNY | 86.52% |
| 2022 Q1 | 184.61 Million CNY | 23.84% |
| 2022 FY | 1.43 Billion CNY | 25.0% |
| 2022 Q4 | 194.22 Million CNY | -52.72% |
| 2022 Q3 | 410.77 Million CNY | 19.29% |
| 2021 Q2 | 218.7 Million CNY | 17.95% |
| 2021 Q4 | 149.06 Million CNY | -33.63% |
| 2021 Q3 | 224.6 Million CNY | 2.7% |
| 2021 FY | 1.15 Billion CNY | 14.84% |
| 2021 Q1 | 185.41 Million CNY | -1.27% |
| 2020 Q3 | 227.51 Million CNY | 45.33% |
| 2020 FY | 1 Billion CNY | -4.79% |
| 2020 Q4 | 187.79 Million CNY | -17.46% |
| 2020 Q2 | 156.54 Million CNY | 117.71% |
| 2020 Q1 | 71.9 Million CNY | -21.2% |
| 2019 Q2 | 197.52 Million CNY | 27.15% |
| 2019 Q1 | 155.35 Million CNY | 48.35% |
| 2019 FY | 1.05 Billion CNY | 82.23% |
| 2019 Q4 | 91.25 Million CNY | -60.79% |
| 2019 Q3 | 232.71 Million CNY | 17.81% |
| 2018 Q1 | 120.46 Million CNY | 32.1% |
| 2018 FY | 577.73 Million CNY | 51.78% |
| 2018 Q3 | 185.58 Million CNY | 11.14% |
| 2018 Q2 | 166.97 Million CNY | 38.61% |
| 2018 Q4 | 104.71 Million CNY | -43.57% |
| 2017 Q3 | 128.67 Million CNY | 24.61% |
| 2017 FY | 380.63 Million CNY | 119.33% |
| 2017 Q4 | 91.19 Million CNY | -29.13% |
| 2017 Q1 | 57.5 Million CNY | -0.91% |
| 2017 Q2 | 103.26 Million CNY | 79.57% |
| 2016 Q4 | 58.03 Million CNY | 15.99% |
| 2016 Q1 | 22.04 Million CNY | -46.66% |
| 2016 Q3 | 50.02 Million CNY | 15.19% |
| 2016 FY | 173.54 Million CNY | 45.07% |
| 2016 Q2 | 43.43 Million CNY | 96.99% |
| 2015 Q2 | 28.87 Million CNY | 65.97% |
| 2015 FY | 119.62 Million CNY | 24.75% |
| 2015 Q4 | 41.33 Million CNY | 29.06% |
| 2015 Q3 | 32.02 Million CNY | 10.93% |
| 2015 Q1 | 17.39 Million CNY | -56.51% |
| 2014 Q4 | 39.99 Million CNY | 80.9% |
| 2014 Q2 | 23.85 Million CNY | 140.2% |
| 2014 Q3 | 22.1 Million CNY | -7.33% |
| 2014 FY | 95.89 Million CNY | 9.03% |
| 2014 Q1 | 9.93 Million CNY | 0.0% |
| 2013 FY | 87.95 Million CNY | 20.36% |
| 2012 FY | 73.07 Million CNY | 2.67% |
| 2011 FY | 71.17 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Joinn Laboratories(China)Co.,Ltd. | 507.09 Million CNY | -27.55% |
| WuXi AppTec Co., Ltd. | 11.87 Billion CNY | 94.552% |
| Autobio Diagnostics Co., Ltd. | 1.36 Billion CNY | 52.641% |
| Thalys Medical Technology Group Inc. | -180.32 Million CNY | 458.693% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 759.76 Million CNY | 14.868% |
| Chemclin Diagnostics Co., Ltd. | 166.28 Million CNY | -288.97% |